VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
VYNE Therapeutics (Nasdaq: VYNE), a clinical-stage biopharmaceutical company specializing in developing therapies for chronic inflammatory and immune mediated conditions, has announced its participation in the upcoming H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference.
The conference, focusing on Skin Diseases, Conditions and Disorders, is scheduled for Thursday, March 27, 2025. Following the presentation, a webcast replay will be accessible on the VYNE website for a period of 90 days.
VYNE Therapeutics (Nasdaq: VYNE), un'azienda biofarmaceutica in fase clinica specializzata nello sviluppo di terapie per condizioni infiammatorie croniche e mediate dal sistema immunitario, ha annunciato la sua partecipazione al prossimo 3° Congresso Virtuale Annuale sulle Malattie Autoimmuni e Infiammatorie di H.C. Wainwright.
Il congresso, incentrato sulle malattie, condizioni e disturbi della pelle, è programmato per giovedì 27 marzo 2025. Dopo la presentazione, una registrazione del webcast sarà disponibile sul sito web di VYNE per un periodo di 90 giorni.
VYNE Therapeutics (Nasdaq: VYNE), una compañía biofarmacéutica en etapa clínica especializada en el desarrollo de terapias para condiciones inflamatorias crónicas y mediadas por el sistema inmunológico, ha anunciado su participación en la próxima 3ª Conferencia Virtual Anual sobre Enfermedades Autoinmunitarias e Inflamatorias de H.C. Wainwright.
La conferencia, centrada en Enfermedades, Condiciones y Trastornos de la Piel, está programada para el jueves 27 de marzo de 2025. Tras la presentación, una repetición del webcast estará disponible en el sitio web de VYNE durante un período de 90 días.
VYNE Therapeutics (Nasdaq: VYNE)는 만성 염증 및 면역 매개 질환을 위한 치료제를 개발하는 임상 단계의 생물 제약 회사로, 다가오는 H.C. Wainwright 제3회 연례 자가면역 및 염증 질환 가상 회의에 참여한다고 발표했습니다.
이번 회의는 피부 질환, 상태 및 장애에 초점을 맞추고 있으며, 2025년 3월 27일 목요일로 예정되어 있습니다. 발표 후, VYNE 웹사이트에서 90일 동안 웹캐스트 재생을 이용할 수 있습니다.
VYNE Therapeutics (Nasdaq: VYNE), une entreprise biopharmaceutique en phase clinique spécialisée dans le développement de thérapies pour des conditions inflammatoires chroniques et médiées par le système immunitaire, a annoncé sa participation à la prochaine 3ème Conférence Virtuelle Annuelle sur les Maladies Auto-immunes et Inflammatoires de H.C. Wainwright.
La conférence, axée sur les maladies, conditions et troubles de la peau, est prévue pour le jeudi 27 mars 2025. Après la présentation, une rediffusion du webcast sera accessible sur le site web de VYNE pendant une période de 90 jours.
VYNE Therapeutics (Nasdaq: VYNE), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Therapien für chronische entzündliche und immunvermittelte Erkrankungen spezialisiert hat, hat seine Teilnahme an der bevorstehenden 3. Virtuellen Jahreskonferenz über Autoimmun- und Entzündungserkrankungen von H.C. Wainwright angekündigt.
Die Konferenz, die sich auf Hauterkrankungen, -zustände und -störungen konzentriert, ist für Donnerstag, den 27. März 2025 geplant. Nach der Präsentation wird eine Webcast-Wiederholung für einen Zeitraum von 90 Tagen auf der VYNE-Website verfügbar sein.
- None.
- None.
BRIDGEWATER, N.J., March 20, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune mediated conditions with high unmet need, today announced that VYNE’s management will participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference (Skin Diseases, Conditions and Disorders) being held on Thursday, March 27, 2025.
Conference Presentation Details:
| Fireside Chat Timing: | Thursday, March 27, 2025, at 11:00 am ET |
| Registration: | Webcast Link |
A webcast replay will be available on the VYNE website for 90 days following the event.
About VYNE Therapeutics Inc.
VYNE is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. VYNE's unique and proprietary BET inhibitors, which comprise its InhiBET™ platform, are designed to overcome limitations of early generation BET inhibitors by leveraging alternative routes of administration and enhanced selectivity.
For more information about VYNE Therapeutics Inc. or its product candidates, visit www.vynetherapeutics.com. VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE’s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission (“SEC”), public conference calls, and webcasts.
Investor Relations:
John Fraunces
LifeSci Advisors, LLC
917-355-2395
jfraunces@lifesciadvisors.com
Tyler Zeronda
VYNE Therapeutics Inc.
908-458-9106
Tyler.Zeronda@VYNEtx.com
Media Relations:
Mike Beyer
Sam Brown Inc.
312-961-2502
mikebeyer@sambrown.com
FAQ
When is VYNE Therapeutics presenting at the H.C. Wainwright Conference 2025?
How long will VYNE's conference presentation webcast be available?
What is the focus of the H.C. Wainwright conference where VYNE is presenting?
What type of conditions does VYNE Therapeutics focus on treating?
